Novel Thiazolidinone/Thiazolo[3,2-]Benzimidazolone-Isatin Conjugates As Apoptotic Anti-proliferative Agents Towards Breast Cancer: One-Pot Synthesis and In Vitro Biological Evaluation

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2018 Jun 14

PMID 29895744

Citations 20

Authors

Mohamed El-Naggar

Wagdy M Eldehna

Hadia Almahli

Amr Elgez

Mohamed Fares

Mahmoud M Elaasser

Hatem A Abdel-Aziz

Affiliations

Soon will be listed here.

Abstract

In connection with our research program on the development of new isatin-based anticancer candidates, herein we report the synthesis of two novel series of thiazolidinone-isatin conjugates (⁻) and thiazolo[3,2-]benzimidazolone-isatin conjugates (⁻), and in vitro evaluation of their antiproliferative activity towards two breast cancer cell lines; triple negative MDA-MB-231, and MCF-7. Compounds and emerged as the most active congeners against MDA-MB-231 cells (IC = 7.6 ± 0.5 and 13.2 ± 1.1 µM, respectively). Compounds and were able to provoke apoptosis in MDA-MB-231 cells, evidenced by the up-regulation of Bax and down-regulation of Bcl-2, besides boosting caspase-3 levels. Hybrid induced a fourfold increase in the percentage of cells at Sub-G₁, with concurrent arrest in G₂-M phase by 2.5-folds. Furthermore, hybrid resulted in a sixfold increase in the percentage of annexin V-FITC positive apoptotic MDA-MB-231 cells as compared with the control. Moreover, the cytotoxic activities of the active conjugates were assessed towards two nontumorigenic cell lines (breast MCF-10A and lung WI-38) where both conjugates and displayed mean tumor selectivity index: 9.6 and 13.9, respectively. Finally, several ADME descriptors were predicted for the active conjugates via a theoretical kinetic study.

Citing Articles

Synthesis of novel quinoline-thiazolobenzimidazolone hybrids as anticancer agents through caspase-dependent apoptosis.

Bouria H, Alliouche H, Chouiter M, Belfaitah A, Pacheco T, Gala V Future Med Chem. 2025; 17(5):543-555.

PMID: 40008604 PMC: 11901420. DOI: 10.1080/17568919.2025.2470112.

Design, synthesis, , and studies of novel isatin-hybrid hydrazones as potential triple-negative breast cancer agents.

Munir I, Batool Z, Khan F, Hussain J, Khan A, Mali S RSC Adv. 2025; 15(2):948-965.

PMID: 39807200 PMC: 11726183. DOI: 10.1039/d4ra07650h.

Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells.

Elias M, Aputen A, Fatima S, Mann T, Karan S, Mikhael M Int J Mol Sci. 2024; 25(15).

PMID: 39125821 PMC: 11312340. DOI: 10.3390/ijms25158252.

A survey of isatin hybrids and their biological properties.

Shu V, Eni D, Ntie-Kang F Mol Divers. 2024; 29(2):1737-1760.

PMID: 38833124 DOI: 10.1007/s11030-024-10883-z.

Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and PI3Kβ kinases.

Elagawany M, Abdel Ghany L, Ibrahim T, Alharbi A, Abdel-Aziz M, El-Labbad E J Enzyme Inhib Med Chem. 2024; 39(1):2311157.

PMID: 38348846 PMC: 10866054. DOI: 10.1080/14756366.2024.2311157.

References

Abdel-Aziz H, Elsaman T, Al-Dhfyan A, Attia M, Al-Rashood K, Al-Obaid A . Synthesis and anticancer potential of certain novel 2-oxo-N'-(2-oxoindolin-3-ylidene)-2H-chromene-3-carbohydrazides. Eur J Med Chem. 2013; 70:358-63. DOI: 10.1016/j.ejmech.2013.09.060. View

Sridhar S, Ramesh A . Synthesis and pharmacological activities of hydrazones, Schiff and Mannich bases of isatin derivatives. Biol Pharm Bull. 2001; 24(10):1149-52. DOI: 10.1248/bpb.24.1149. View

Kaminskyy D, Khyluk D, Vasylenko O, Zaprutko L, Lesyk R . A facile synthesis and anticancer activity evaluation of spiro[thiazolidinone-isatin] conjugates. Sci Pharm. 2011; 79(4):763-77. PMC: 3221502. DOI: 10.3797/scipharm.1109-14. View

Abdel-Aziz H, Eldehna W, Keeton A, Piazza G, Kadi A, Attwa M . Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in vitro pharmacological profiling. Drug Des Devel Ther. 2017; 11:2333-2346. PMC: 5557401. DOI: 10.2147/DDDT.S140164. View

Delbridge A, Grabow S, Strasser A, Vaux D . Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016; 16(2):99-109. DOI: 10.1038/nrc.2015.17. View

Ke S, Shi L, Yang Z . Discovery of novel isatin-dehydroepiandrosterone conjugates as potential anticancer agents. Bioorg Med Chem Lett. 2015; 25(20):4628-31. DOI: 10.1016/j.bmcl.2015.08.041. View

Meng G, Zheng M, Wang M, Tong J, Ge W, Zhang J . Design and synthesis of new potent PTP1B inhibitors with the skeleton of 2-substituted imino-3-substituted-5-heteroarylidene-1,3-thiazolidine-4-one: Part I. Eur J Med Chem. 2016; 122:756-769. DOI: 10.1016/j.ejmech.2016.05.060. View

Taher A, Khalil N, Ahmed E . Synthesis of novel isatin-thiazoline and isatin-benzimidazole conjugates as anti-breast cancer agents. Arch Pharm Res. 2011; 34(10):1615-21. DOI: 10.1007/s12272-011-1005-3. View

Nagarsenkar A, Guntuku L, Guggilapu S, K D, Gannoju S, Naidu V . Synthesis and apoptosis inducing studies of triazole linked 3-benzylidene isatin derivatives. Eur J Med Chem. 2016; 124:782-793. DOI: 10.1016/j.ejmech.2016.09.009. View

10.

Eldehna W, Altoukhy A, Mahrous H, Abdel-Aziz H . Design, synthesis and QSAR study of certain isatin-pyridine hybrids as potential anti-proliferative agents. Eur J Med Chem. 2014; 90:684-94. DOI: 10.1016/j.ejmech.2014.12.010. View

11.

Eldehna W, Fares M, Abdel-Aziz M, Abdel-Aziz H . Design, synthesis and antitubercular activity of certain nicotinic Acid hydrazides. Molecules. 2015; 20(5):8800-15. PMC: 6272317. DOI: 10.3390/molecules20058800. View

12.

Hu W, Kavanagh J . Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 2003; 4(12):721-9. DOI: 10.1016/s1470-2045(03)01277-4. View

13.

Soliman D, Eldehna W, Ghabbour H, Kabil M, Abdel-Aziz M, Abdel-Aziz H . Novel 6-Phenylnicotinohydrazide Derivatives: Design, Synthesis and Biological Evaluation as a Novel Class of Antitubercular and Antimicrobial Agents. Biol Pharm Bull. 2017; 40(11):1883-1893. DOI: 10.1248/bpb.b17-00361. View

14.

Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29. DOI: 10.3322/caac.21208. View

15.

McIlwain D, Berger T, Mak T . Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 2015; 7(4). PMC: 4382736. DOI: 10.1101/cshperspect.a026716. View

16.

Eldehna W, Abo-Ashour M, Nocentini A, Gratteri P, Eissa I, Fares M . Novel 4/3-((4-oxo-5-(2-oxoindolin-3-ylidene)thiazolidin-2-ylidene)amino) benzenesulfonamides: Synthesis, carbonic anhydrase inhibitory activity, anticancer activity and molecular modelling studies. Eur J Med Chem. 2017; 139:250-262. DOI: 10.1016/j.ejmech.2017.07.073. View

17.

Eldehna W, Fares M, Ceruso M, Ghabbour H, Abou-Seri S, Abdel-Aziz H . Amido/ureidosubstituted benzenesulfonamides-isatin conjugates as low nanomolar/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII. Eur J Med Chem. 2016; 110:259-66. DOI: 10.1016/j.ejmech.2016.01.030. View

18.

Solomon V, Hu C, Lee H . Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity. Bioorg Med Chem. 2009; 17(21):7585-92. DOI: 10.1016/j.bmc.2009.08.068. View

19.

Barnard M, Boeke C, Tamimi R . Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta. 2015; 1856(1):73-85. DOI: 10.1016/j.bbcan.2015.06.002. View

20.

Gudipati R, Anreddy R, Manda S . Synthesis, anticancer and antioxidant activities of some novel N-(benzo[d]oxazol-2-yl)-2-(7- or 5-substituted-2-oxoindolin-3-ylidene) hydrazinecarboxamide derivatives. J Enzyme Inhib Med Chem. 2011; 26(6):813-8. DOI: 10.3109/14756366.2011.556630. View